SCHEMBL30748930

SCHEMBL30748930

COc1cc(N2CCOCC2)ccc1N1CC(C)(C)c2c(NCC(F)(F)F)nc(CO[Si](C)(C)C(C)(C)C)nc21

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TTK P33981 6/20 0.42
SIK1 P57059 2/20 0.37
SIK2 Q9H0K1 2/20 0.37
SIK3 Q9Y2K2 2/20 0.37
PIK3CA P42336 5/20 0.35
PSEN1 P49768 2/20 0.35
PSEN2 P49810 2/20 0.35
APH1B Q8WW43 2/20 0.35
NCSTN Q92542 2/20 0.35
APH1A Q96BI3 2/20 0.35
PSENEN Q9NZ42 2/20 0.35
ULK1 O75385 1/20 0.34
ALDH1A1 P00352 1/20 0.34
MAPT P10636 1/20 0.34
MAPK1 P28482 1/20 0.34
INSR P06213 1/20 0.33
ALK Q9UM73 1/20 0.33
EGFR P00533 1/20 0.33
LRRK2 Q5S007 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30749056 0.89 TTK (0.43) TTKSIK1SIK2SIK3PIK3CA
SCHEMBL30748822 0.87 PSEN1 (0.39) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL30748773 0.86 PIK3CA (0.41) TTKPIK3CAMAPTINSRALK
SCHEMBL31691490 0.78 PLK4 (0.40) PIK3CAALDH1A1MAPT
SCHEMBL30749134 0.78 LRRK2 (0.43) TTKPIK3CAPSEN1PSEN2APH1B
SCHEMBL30748900 0.74 PSEN1 (0.44) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL31691453 0.73 PIK3CA (0.36) TTKPIK3CAMAPT
SCHEMBL30749106 0.72 PSEN1 (0.37) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL30749157 0.71 PIK3CA (0.47) PIK3CAALDH1A1MAPTINSRALK
SCHEMBL15333995 0.69 PIK3CA (0.42) TTKPIK3CAPSEN1PSEN2APH1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT TTK 4131/4885SIK1 2001/4885SIK2 1999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.